CD274 and non-small cell lung carcinoma: Nonetheless, multiple studies have demonstrated the prognostic value of CTCs in patients with NSCLC, and these studies indicated that dynamic changes in the number of PD-L1+ CTCs may help monitor response to treatment (82–85).